Researchers tested the drug in a randomized, double-blind placebo controlled study of 412 patients.
Here’s what you should know.
1. The drug significantly reduces C. difficile infection.
2. Of the patients, there were seven confirmed infections in the placebo group and two in the ribaxamase group.
3. Patients receiving ribaxamase achieved a 71.4 percent relative risk reduction in CDI rates compared to patients receiving a placebo.
4. Adverse events reported were comparable between both groups.
More articles on gastroenterology:
Non-surgical endoscopic sleeve gastroplasty effective weight loss treatment for those with limited options
GI leader to know: Dr. Richard Panicco of Southwest Gastroenterology Associates
Study identifies biomarkers that predict which hepatitis C, cirrhosis patients improve with treatment — 2 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.